文献速递泌尿男性生殖肿瘤

高危前列腺癌全盆腔对比单纯前列腺放疗:POP-RT III期随机试验结果

Prostate-Only Versus Whole-Pelvic Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer (POP-RT): Outcomes From Phase III Randomized Controlled Trial.
PubMed 文献 · J Clin Oncol · 2021-01-26

POP-RT是一项单中心III期随机对照试验,纳入224例淋巴结转移风险≥20%的高危前列腺癌患者,1:1随机接受单纯前列腺放疗(PORT)或全盆腔放疗(WPRT)。中位随访68个月,WPRT组5年生化失败无生存(BFFS)和无病生存(DFS)均显著优于PORT组,但总生存(OS)无显著差异。

要点

  • 高危前列腺癌预防性全盆腔放疗较单纯前列腺放疗显著改善5年BFFS和DFS。
  • 全盆腔放疗未显著改善5年总生存。
  • BFFS和DFS获益在预后亚组中一致。

核心结论

  • 高危局部晚期前列腺癌预防性盆腔照射较单纯前列腺放疗改善BFFS和DFS,但OS未见差异。

研究设计与样本

  • III期单中心随机对照试验,纳入224例淋巴结转移风险≥20%的前列腺腺癌患者,1:1随机至PORT组(114例)或WPRT组(110例)。

主要发现

  • 中位随访68个月,WPRT组与PORT组分别记录7例和25例生化失败,11例和13例死亡。
  • 5年BFFS:WPRT组95.0%(95%CI 88.4-97.9)对比PORT组81.2%(95%CI 71.6-87.8),未校正HR 0.23(95%CI 0.10-0.52;P<.0001)。
  • 5年DFS:WPRT组89.5%对比PORT组77.2%,HR 0.40(95%CI 0.22-0.73;P=.002)。
  • 5年OS:WPRT组92.5%对比PORT组90.8%,HR 0.92(95%CI 0.41-2.05;P=.83)。
  • 5年无远处转移生存:WPRT组95.9%对比PORT组89.2%,HR 0.35(95%CI 0.15-0.82;P=.01)。

临床怎么用

  • 对于淋巴结转移风险≥20%的高危前列腺癌患者,可考虑预防性全盆腔放疗以改善生化控制和疾病控制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We report the clinical outcomes of a randomized trial comparing prophylactic whole-pelvic nodal radiotherapy to prostate-only radiotherapy (PORT) in high-risk prostate cancer. METHODS: This phase III, single center, randomized controlled trial enrolled eligible patients undergoing radical radiotherapy for node-negative prostate adenocarcinoma, with estimated nodal risk ≥ 20%. Randomization was 1:1 to PORT (68 Gy/25# to prostate) or whole-pelvic radiotherapy (WPRT, 68 Gy/25# to prostate, 50 Gy/25# to pelvic nodes, including common iliac) using computerized stratified block randomization, stratified by Gleason score, type of androgen deprivation, prostate-specific antigen at diagnosis, and prior transurethral resection of the prostate. All patients received image-guided, intensity-modulated radiotherapy and minimum 2 years of androgen deprivation therapy. The primary end point was 5-year biochemical failure-free survival (BFFS), and secondary end points were disease-free survival (DFS) and overall survival (OS). RESULTS: From November 2011 to August 2017, a total of 224 patients were randomly assigned (PORT = 114, WPRT = 110). At a median follow-up of 68 months, 36 biochemical failures (PORT = 25, WPRT = 7) and 24 deaths (PORT = 13, WPRT = 11) were recorded. Five-year BFFS was 95.0% (95% CI, 88.4 to 97.9) with WPRT versus 81.2% (95% CI, 71.6 to 87.8) with PORT, with an unadjusted hazard ratio (HR) of 0.23 (95% CI, 0.10 to 0.52; P < .0001). WPRT also showed higher 5-year DFS (89.5% v 77.2%; HR, 0.40; 95% CI, 0.22 to 0.73; P = .002), but 5-year OS did not appear to differ (92.5% v 90.8%; HR, 0.92; 95% CI, 0.41 to 2.05; P = .83). Distant metastasis-free survival was also higher with WPRT (95.9% v 89.2%; HR, 0.35; 95% CI, 0.15 to 0.82; P = .01). Benefit in BFFS and DFS was maintained across prognostic subgroups. CONCLUSION: Prophylactic pelvic irradiation for high-risk, locally advanced prostate cancer improved BFFS and DFS as compared with PORT, but OS did not appear to differ.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Murthy V, Maitre P, Kannan S, et al. Prostate-Only Versus Whole-Pelvic Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer (POP-RT): Outcomes From Phase III Randomized Controlled Trial. J Clin Oncol. 2021. PMID: 33497252. doi:10.1200/JCO.20.03282

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。